Good News! Pfizer’s Vaccine Safe And 95% Effective To Fight COVID-19; Says Final Study Result
Final study results suggest that Pfizer’s vaccine is safe and 95% effective in treating Covid-19. Read on to know the details.
Pfizer proved to be a ray of hope in the fight against the worldwide pandemic. According to the company, the vaccine showed 95 per cent efficacy in the late-stage trial on Wednesday. As per the report, the efficacy of the vaccine developed in partnership with German BioNTech SE was consistent across age and ethnicity demographics. There were no major side effects. The report suggests this to be a sign that immunization could be employed broadly around the world.
Watch the news video here:
The efficacy of the vaccine in adults above the age of 65 years, who are at risk, was over 94 per cent. The company also said that it plans to apply for emergency US authorisation within days. As per the final results that comes just one week after the initial results, the trial showed the vaccine to be more than 90 per cent effective. On the other hand, Moderna Inc showed similar results after it released its preliminary data on Monday.
According to a news portal, the influential panel of outside experts is likely to meet during the second week of December to discuss the Pfizer application. Later, the committee is likely to scrutinize data in the following week from the biotech company Moderna. As per the report, Health and Human Services Secretary Alex Azar said that the two vaccines could be authorized by the FDA and be ready within weeks for distribution.
In other news, a fast and affordable Coronavirus testing kit has been launched in Delhi today. The kit can provide results in 40 minutes and is based on the gene-editing technology CRISPR called Feluda. It is launched by Tata groups in collaboration with the Apollo group of hospitals, as reported. The testing kit is relatively cheaper than the current gold standard RT-PCR and equally accurate. It also helps in scaling up COVID-19 testing as it is widely available with laboratories and science institutions.
According to a statement by TataMD, “TataMD Check’s simpler, more agile testing process delivers quick results and enables more patients to be tested by bringing diagnostics closer to the patient. Testing can be performed swiftly and in small batches using simple, inexpensive, off-the-shelf thermocyclers instead of expensive qPCR equipment. This will enable diagnostic labs to achieve higher test throughputs and scale-up volumes with minimal capital investments and set-up time.”
Head over to ZEE5 for all the trending news and updates.